

Emcure to expand in gynaecology

Pune-headquartered Emcure Pharmaceuticals plans to expand its gynaecology and dermatology product portfolio for the Indian market in FY26, the company's top executive said on Thursday.

"In women's health, we launched a portfolio of products in the menopause and PCOS segment [in FY25]," the company's chief executive officer (CEO) and managing director (MD) Satish Mehta said in a post-earnings call. "We are also in the process of deepening our presence in the gynaecology segment with further launches in FY26," he added.

The firm, which was listed on the exchanges in July 2024, reported a Q4 profit after tax of ₹197 crore in FY25, up 63% year-on-year. Revenue rose 19.5% to ₹2,116 crore.

The revenue growth was driven by 24.8% growth in its domestic business and 15.6% growth in its international business. **JESSICA JANI**